Open AccessRegional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations
Author(s) -
М. В. Сура,
T. N. Ignatova,
Н. С. Руднева,
Yu. N. Sukhanova,
N. G. Ulyanova,
A. S. Khudyaev,
Valery A. Shelyakin,
D. V. Scherbakov
Publication year - 2018
Publication title -
farmakoèkonomika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.177
H-Index - 3
eISSN - 2070-4933
pISSN - 2070-4909
DOI - 10.17749/2070-4909.2018.11.2.044-052
Subject(s) - reimbursement , payment , medical expenses , medical insurance , actuarial science , medical care , adaptation (eye) , business , national health insurance , medicine , health care , medical emergency , finance , family medicine , environmental health , economics , economic growth , psychology , neuroscience , population
The existing model of financial support of medical assistance for clinical-statistical groups (CSGs) in 2018 provides for the reimbursement for hospital stay expenses by the compulsory medical insurance fund in patients claiming the need for genetically engineered biological products (GiBP) during their stay in a day-care or 24-hour inpatient facility. The payment is made to CSG no. 121 in a day care and to CSG no. 316 in a 24-hour inpatient facility. The heterogeneity of the expenses for therapy with GiBP necessitates further division of the Federal CSGs into subgroups located in the constituent parts of the Russian Federation. This process has been initiated in some parts of the country, and it is seen as a way of regional adaptation of the Federal Medical insurance model. The proposed subdivision of the Federal CSGs allows for setting the tariffs reflecting the real expenses incurred by a local medical organization due to the therapeutic use of GiBP. The models of such specific CSGs proposed by RF subjects (after an expert evaluation) can be taken as a basis for updating the Federal CSG model, taking into account the differences in the costs of different drug therapy regimens.